Akero Therapeutics (AKRO) Price & Analysis

Compare

650 Followers

AKRO Stock Chart & Stats

Day’s Range― - ―

52-Week Range$21.34 - $58.40

Previous CloseN/A

Volume136.04K

Average Volume (3M)2.36M

Market Cap

$3.72B

Enterprise Value$3.66B

Total Cash (Recent Filing)$742.32M

Total Debt (Recent Filing)$37.19M

Price to Earnings (P/E)―

Beta1.15

Next Earnings

Nov 12, 2025

EPS Estimate

-0.93

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.86

Shares Outstanding79,988,976

10 Day Avg. Volume4,658,668

30 Day Avg. Volume2,364,552

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.98

Enterprise Value/Revenue913.88K

Enterprise Value/Gross Profit3.66M

Enterprise Value/Ebitda-13.09

Forecast

1Y Price Target

$60.22

Price Target Upside11.77% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering10

Bulls Say, Bears Say

Bulls Say

Acquisition BenefitsNovo's acquisition of Akero is expected to strengthen Akero's M&A prospects and make the company a more compelling takeout target.

Clinical DataAkero's efruxifermin is well positioned with best-in-class potential in F2/F3 MASH and in F4 MASH given groundbreaking data in these more difficult to treat patients.

Strategic FitThe acquisition is a strategic and complementary fit with Novo's recent approval of Wegovy in F2/3 MASH.

Bears Say

Bidder AssumptionsGiven the proposed acquisition, the rating is moved to Neutral with the assumption that no additional bidder is expected to emerge.

Price Target ReductionThe price target has been decreased to $58 based on the acquisition deal terms.

Stock Rating DowngradeThe stock rating has been downgraded to Hold from Buy due to the acquisition.

Akero Therapeutics News

Akero Therapeutics downgraded to Hold from Buy at TD Cowen

TD Cowen downgraded Akero Therapeutics (AKRO) to Hold from Buy with a price target of $58, down from...

18h ago

AKRO

Madrigal Pharmaceuticals price target raised to $590 from $500 at Oppenheimer

Oppenheimer analyst Jay Olson raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $590 from $500 and...

1d ago

NVO

AKRO

Akero Therapeutics downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright downgraded Akero Therapeutics (AKRO) to Neutral from Buy with a price target of $54, down from...

1d ago

AKRO

Akero Therapeutics downgraded to Hold from Buy at Clear Street

Clear Street downgraded Akero Therapeutics (AKRO) to Hold from Buy with a price target of $54, up from...

2d ago

NVO

AKRO

Akero Therapeutics downgraded to Peer Perform from Outperform at Wolfe Research

Wolfe Research analyst Andy Chen downgraded Akero Therapeutics (AKRO) to Peer Perform from Outperform following Novo Nordisk’s (NVO)...

2d ago

AKRO

Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!

Earnings reports, deals, and a stock market warning make up the top market stories on Thursday. ...

2d ago

AMD

DAL

Akero Therapeutics rises 16.6%

Akero Therapeutics (AKRO) is up 16.6%, or $7.74 to $54.23. Published first on TheFly – the ultimate source...

2d ago

AKRO

Midday Fly By: Delta beats, PepsiCo names new CFO

The major averages were broadly lower near noon, giving back some of yesterday’s gains as the U.S. government...

2d ago

AZZ

Akero downgraded to Market Perform from Outperform at LifeSci Capital

LifeSci Capital analyst Rami Katkhuda downgraded Akero Therapeutics (AKRO) to Market Perform from Outperform with a $58 price...

2d ago

AKRO

Akero Therapeutics downgraded to Hold from Buy at Jefferies

Jefferies downgraded Akero Therapeutics (AKRO) to Hold from Buy with a price target of $56, down from $75,...

2d ago

NVO

AKRO

Akero Therapeutics downgraded to Hold from Buy at Canaccord

Canaccord downgraded Akero Therapeutics (AKRO) to Hold from Buy with a price target of $54, down from $73,...

2d ago

AKRO

M&A News: Akero Therapeutics Stock (AKRO) Zooms 19% after Novo Nordisk Buys it for $5.2B

Shares in Akero Therapeutics ($AKRO) raced 19% higher today after it was bought by pharmaceutical giant Novo Nordisk...

2d ago

NVO

AKRO

Hold Rating on Akero Therapeutics Amid NOVO Acquisition and Regulatory Uncertainties

Akero Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ritu Baral from...

22h ago

AKRO

Akero Therapeutics Acquired by Novo Nordisk for $5.2B

The latest announcement is out from Akero Therapeutics ( ($AKRO) ). On October 9, 2025, Akero Therapeutics announced...

2d ago

AKRO

AKRO FAQ

What was Akero Therapeutics’s price range in the past 12 months?

Akero Therapeutics lowest stock price was $21.34 and its highest was $58.40 in the past 12 months.

What is Akero Therapeutics’s market cap?

Akero Therapeutics’s market cap is $3.72B.

When is Akero Therapeutics’s upcoming earnings report date?

Akero Therapeutics’s upcoming earnings report date is Nov 12, 2025 which is in 32 days.

How were Akero Therapeutics’s earnings last quarter?

Akero Therapeutics released its earnings results on Aug 08, 2025. The company reported -$0.86 earnings per share for the quarter, beating the consensus estimate of -$0.917 by $0.057.

Is Akero Therapeutics overvalued?

According to Wall Street analysts Akero Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Akero Therapeutics pay dividends?

Akero Therapeutics does not currently pay dividends.

What is Akero Therapeutics’s EPS estimate?

Akero Therapeutics’s EPS estimate is -0.93.

How many shares outstanding does Akero Therapeutics have?

Akero Therapeutics has 79,988,976 shares outstanding.

What happened to Akero Therapeutics’s price movement after its last earnings report?

Akero Therapeutics reported an EPS of -$0.86 in its last earnings report, beating expectations of -$0.917. Following the earnings report the stock price went up 0.02%.

Which hedge fund is a major shareholder of Akero Therapeutics?

Currently, no hedge funds are holding shares in AKRO

Akero Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-31.14%

Trailing 12-Months

Asset Growth

28.22%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Akero Therapeutics

Akero Therapeutics (AKRO) is a clinical-stage biopharmaceutical company focused on developing and commercializing transformative treatments for patients with serious metabolic diseases. The company's primary focus is on nonalcoholic steatohepatitis (NASH), a severe form of nonalcoholic fatty liver disease. Akero's lead product candidate, Efruxifermin (EFX), is a novel Fc-FGF21 fusion protein designed to address the underlying causes of NASH by reducing liver fat, inflammation, and fibrosis.

Akero Therapeutics (AKRO) Earnings & Revenues

Historic Earnings Reports

AKRO Stock 12 Month Forecast

Average Price Target

$60.22

▲(11.77% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"17":"$17","34":"$34","51":"$51","68":"$68","85":"$85"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":84,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$84.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":60.22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$60.22</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":54,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$54.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[17,34,51,68,85],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,46.55,49.43076923076923,52.31153846153846,55.19230769230769,58.073076923076925,60.95384615384616,63.83461538461538,66.71538461538461,69.59615384615384,72.47692307692307,75.3576923076923,78.23846153846154,81.11923076923077,{"y":84,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,46.55,47.60153846153846,48.653076923076924,49.70461538461538,50.75615384615384,51.80769230769231,52.85923076923077,53.91076923076923,54.96230769230769,56.01384615384615,57.065384615384616,58.11692307692307,59.16846153846154,{"y":60.22,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,46.55,47.12307692307692,47.69615384615384,48.26923076923077,48.84230769230769,49.41538461538461,49.988461538461536,50.56153846153846,51.13461538461539,51.707692307692305,52.28076923076923,52.85384615384615,53.426923076923075,{"y":54,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":18.82,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.35,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.2,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.33,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.01,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.82,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.08,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.12,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.64,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.31,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.37,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.44,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.55,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >